NEW YORK – Caris Life Sciences said Monday that it has closed a $168 million funding round intended to support the company in expanding its genomic testing platform.

纽约——Caris Life Sciences公司周一表示，已完成一轮1.68亿美元的融资，旨在支持该公司扩展其基因组测试平台。

Existing investor Braidwell led the financing with participation from new investors Perceptive Advisors, Woodline, and Ghisallo, among others. Several other existing investors also joined, including Millennium Management and First Light Asset Management.

现有投资者布雷德威尔领投了本轮融资，新投资者珀ceptive Advisors、伍德莱恩和吉萨洛等也参与其中。其他几位现有投资者也加入了此轮融资，包括千禧管理公司和第一光资产管理公司。

'This raise will help us bring our market-leading science and technologies to as many patients as possible and further our goal of revolutionizing precision medicine,' said Caris CEO David Halbert. 'We plan to unlock the full potential of precision medicine by comprehensively interrogating cancer at the molecular level and enabling the delivery of transformative applications of molecular science,' he added..

“这次融资将帮助我们把领先的科学和技术带给尽可能多的患者，并进一步实现我们革新精准医疗的目标，”Caris首席执行官大卫·哈尔伯特表示。“我们计划通过在分子水平上全面探究癌症，释放精准医疗的全部潜力，并实现分子科学的变革性应用，”他补充道。

The company's tests include the recently launched MI Cancer Seek, a simultaneous Whole Exome and Whole Transcriptome Sequencing-based assay with FDA-approved companion diagnostic indications, and the liquid biopsy therapy selection test Caris Assure.

公司测试包括最近推出的MI Cancer Seek，这是一款基于全外显子组和全转录组测序的同时检测方法，并具有FDA批准的伴随诊断适应症，以及液体活检治疗选择测试Caris Assure。